

Date: February 11, 2022

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

Subject: Outcome of the Board Meeting held on 11th February 2022, Friday, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

SYMBOL: AJOONI

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Friday, 11th February 2022 at 11.30 A.M concluded at 12.25 p.m.. Following transactions were considered and approved:

1. Un-audited Financial Results for the quarter ended 31st December, 2021.
2. Limited Review Report from the auditor for the quarter ended 31st December, 2021.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

Swati Yadav
Company Secretary
(ACS: 39179)



AJOONI BIOTECH LIMITED

CIN : L85190PB201OPLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2021 (In Lakhs)

PARTICULARS	Quarter Ended				Year Ended (Audited)
	31.12.2021	30.09.2021	31.12.2020	Period Ended (Unaudited) 31.12.2020	
I Income				31.12.2021	31.03.2021
Revenue from operations	1,928.77	1,839.19	1,290.88	5,352.59	5,103.88
Other income	0.66	0.81	0.45	2.39	1.72
Total income from operations	1,929.43	1,840.00	1,291.33	5,354.98	5,105.60
II Expenses					
Cost of Material Consumed	1,721.58	1,562.05	1,083.18	4,626.45	4,335.59
Change in Inventories	19.50	(15.22)	27.95	2.79	-34.32
Employee benefit expenses	44.85	42.03	35.35	124.98	114.78
Finance costs	7.89	22.18	22.44	43.37	58.40
Depreciation and amortization expenses	34.39	28.86	18.25	82.19	57.75
Payment to NSE					
Other expenses	45.86	154.81	106.26	333.75	290.20
Total expenses	1,874.07	1,794.71	1,293.43	5,213.53	5,055.18
III Profit/(Loss) before exceptional items and tax	55.36	45.29	(2.10)	141.45	50.42
IV Exceptional items					
V Profit/(Loss) before tax	55.36	45.29	(2.10)	141.45	50.42
VI Tax expenses					
a) Current tax	12.76	11.78		36.78	15.03
b) Deferred tax	1.8	1.75	-	4.60	1.91
b) Mat Credit	-	-	-	-	-
VII Net Profit/(Loss) for the period/year	44.40	35.26	(2.10)	109.27	37.30
VIII Other comprehensive income (net of tax)					
Items that will not be reclassified to profit or loss:					
		4.93	-	4.93	(181)
Total other comprehensive income					
IX Total comprehensive income for the period/year (VII+VIII)	44.40	40.19	(2.10)	114.20	(144.03)
X Paid-up equity share capital (face value of the share shall be indicated)	1,000.55	1,000.55		1,000.55	1,000.55
XI Other equity (excluding revaluation reserve)	681.91	637.51		681.91	564.51



XII EPS in Rs. (Face Value of Rs.10/- each)*						
-Basic		0.44	0.35	(0.02)	1.09	0.45
-Diluted		0.44	0.35	(0.02)	1.09	0.45
Notes:						
1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 11.02.2022 after being reviewed by the Audit Committee.						
2. The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.						
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.						

For Ajpoint Biotech Limited

 Jasjot Singh
 Managing Director
 DIN: 01937631

Date: 11/02/2022

Place : Mohali

AJOONI BIOTECH LIMITED
CIN : L85190PB2010PLC040162
Statement of Assets and Liabilities
For the Year ended on 31st DECEMBER 2021

in Rs.

PARTICULARS	30TH SEPTEMBER 2021	31ST MARCH 2021
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	63,910,410	51,617,081
b) Financial Assets		
(1) Non-Current Investments	10,787,122	11,482,856
(2) Advances		
c) Deferred Tax Asset	1,925,029	1,465,029
d) Other Non Current Assets	352,030	1,407,030
(2) Current Assets		
a) Inventories	49,106,973	53,762,090
b) Financial Assets		
(1) Cash & Cash Equivalent	461,962	2,440,976
(2) Short Term Loans and advances	22,018,503	19,882,931
(3) Trade Receivables	160,552,032	137,117,389
c) Other Current Asset		1,087,547
TOTAL Rs.	309,114,061	280,262,930

II EQUITY AND LIABILITIES

(1) Equity		
a) Equity Share Capital	100,055,820	100,055,820
b) Other Equity	67,871,410	56,451,410
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	29,928,703	18,979,313
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	43,909,638	48,857,260
(2) Trade Payables	60,228,284	54,003,957
b) Other Current Liabilities	3,442,207	411,890
c) Current tax liabilities (Net)	3,678,000	1,503,280
TOTAL Rs.	309,114,062	280,262,930

0

Date: 11/02/2022
Place: Mohali

For Ajooni Biotech Limited


Jasjot Singh
Managing Director
DIN: 01937631



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of **M/s. Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended

31st DECEMBER 2021 (“the Statement”) attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to “Review of Interim Financial Information performed by the independent auditor of the entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.
Chartered Accountants

CA Konica Madan
Partner

M.No. 5484

Date : 11.02.2022

UDIN : 22547759ABIFUF5136